3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
11
Prostatic Neoplasms
7
Fallopian Tube Neoplasms
4
Neoplasms
3
Neoplasm Metastasis
3
Breast Neoplasms
3
Prostatic Neoplasms, Castration-Resistant
2
Carcinoma, Ovarian Epithelial
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
SCLC,Extensive Stage
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Carcinosarcoma
1
Oropharyngeal Neoplasms
1
Mouth Neoplasms
1
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
1
Metastatic Castration-sensitive Prostate Cancer
1
Lung Neoplasms
1
Laryngeal Diseases
1
Hereditary Sensory and Autonomic Neuropathies
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Glioblastoma
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Neuroendocrine
1
Interventions
Cisplatin
15
Gemcitabine
14
durvalumab
9
pembrolizumab
7
Oxaliplatin
6
Bevacizumab
6
Capecitabine
5
lenvatinib
4
S 1 (combination)
3
Liquid Biopsy
3
Irinotecan
3
Folfox protocol
3
Fluorouracil
3
Carboplatin
3
zanidatamab
2
tremelimumab
2
envafolimab
2
Trastuzumab
2
Nivolumab
2
Leucovorin
2
Injections
2
Blood Specimen Collection
2
Albumin-Bound Paclitaxel
2
trastuzumab deruxtecan
1
toripalimab
1
tislelizumab
1
poly ICLC
1
niraparib
1
neratinib
1
larotrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
niraparib
×
90 days
×
Clear all
NCT05615818
2026-05-19
SAFIR-ABC10
UNICANCER
Phase 3
Recruiting
800 enrolled